“FIB-4 ≥1.3 Is Correlated With Increased DKD Risk in T2D, But SGLT2i Therapy That Lowers FIB-4 Attenuates This ”. Diabzen, vol. 3, no. 4, Dec. 2025, pp. 120-7, https://www.thediabzen.com/index.php/d/article/view/34.